Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
A research-driven breakdown of what's actually inside the most popular peptide blend — and why fixed ratios create pharmacological problems your supplier won't mention.
Inside the KLOW quad stack: GHK-Cu, BPC-157, TB-500, and KPV. We examine the pharmacokinetic mismatches, the missing human trials, and why individual titration beats fixed-ratio convenience.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through three different mechanisms — and the honest protocol leads with the one that has actually passed regulatory scrutiny.
The peptide approach to blood sugar regulation splits into three distinct classes — incretin receptor agonists (GLP-1, dual GLP-1/GIP), mitochondrial-derived peptides (MOTS-c), and Khavinson bioregulators (Pankragen). Each sits on a different shelf of the evidence stack, each has a different risk profile, and the most common protocol error is treating them as interchangeable.
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
CJC-1295 is a 29-amino acid GHRH analog engineered to resist enzymatic breakdown. It stimulates endogenous GH pulses rather than flooding the system with synthetic hormone, offering a fundamentally different risk-benefit profile to direct HGH therapy.
35+
Articles
18
Categories